Citation Impact
Citing Papers
Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) - gastrointestinal cancer group
2008
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Gastric cancer
2016 Standout
Adjustment, the hands and healing
1985
Microsatellite instability in colorectal cancer—the stable evidence
2010
Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas
1995
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
2006 Standout
The therapeutic potential of interleukin-6 hyperagonists and antagonists
1997
Microsatellite Instability in Colorectal Cancer
2010 Standout
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
2014 Standout
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial
2003 Standout
A Phase II Trial of Tetrathiomolybdate After Surgery for Malignant Mesothelioma: Final Results
2008
Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice
2006 Standout
Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial
2010 Standout
Disgust as a disease-avoidance mechanism.
2009 Standout
Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome
2008 Standout
A Reevaluation of the Exclusion Criteria Used in Antidepressant Efficacy Trials
2002
Role of microsatellite instability in the management of colorectal cancers
2012
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
2014 Standout
Wound Healing Dressings and Drug Delivery Systems: A Review
2007 Standout
Colorectal cancer
2013 Standout
Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer
2015 Standout
Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy
2011
POEMS syndrome: A study of 25 cases and a review of the literature
1994
Colorectal cancer
2019 Standout
Adjuvant Therapy of Stage II and III Colon Cancer
2005
Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas
1995 Standout
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Adjuvant Therapy for Colon Cancer 2005: New Options in the Twenty-First Century
2006
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
2007 Standout
Adjuvant therapy for colon cancer: Present and perspectives
2008
Gastric cancer
2020 Standout
Recombinant Human Single Chain Fv Antibodies Recognizing Human Interleukin-6
1998 StandoutNobel
The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer
2013 Standout
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
Cancer-related inflammation and treatment effectiveness
2014 Standout
Expectations and associations that heal: Immunomodulatory placebo effects and its neurobiology
2006
Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation
2011
Docetaxel (Taxotere®)-cisplatin (TC): An effective drug combination in gastric carcinoma
2000
Anemia of Chronic Disease
2005 Standout
Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP
1997 Standout
Perineural invasion in cancer
2009 Standout
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data
2006
Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803
2009
Biomedical Practice and Anthropological Theory: Frameworks and Directions
1983 Standout
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
2006 Standout
High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy
2010
Role of pain in placebo analgesia.
1979
A bioadhesive patch cervical drug delivery system for the administration of 5-fluorouracil to cervical tissue
1995
Weekly Infusional High-Dose Fluorouracil (HD-FU), HD-FU Plus Folinic Acid (HD-FU/FA), or HD-FU/FA Plus Biweekly Cisplatin in Advanced Gastric Cancer: Randomized Phase II Trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie
2007
Chemotherapy for advanced gastric cancer
2017 Standout
Compliance, adherence and the therapeutic alliance: Steps in the development of self-care
1978 Standout
Irinotecan Fluorouracil Plus Leucovorin Is Not Superior to Fluorouracil Plus Leucovorin Alone As Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803
2007
The Nature of Suffering and the Goals of Medicine
1982 Standout
Knowledge and Use of Placebos by House Officers and Nurses
1979
Phase II Multi-Institutional Randomized Trial of Docetaxel Plus Cisplatin With or Without Fluorouracil in Patients With Untreated, Advanced Gastric, or Gastroesophageal Adenocarcinoma
2005
A Comprehensive Review of the Placebo Effect: Recent Advances and Current Thought
2007 Standout
Docetaxel and Continuous-Infusion Fluorouracil Versus Epirubicin, Cisplatin, and Fluorouracil for Advanced Gastric Adenocarcinoma: A Randomized Phase II Study
2005
Advances in Copper Complexes as Anticancer Agents
2013 Standout
What Happens When Hospitalized Patients See Their Own Records
1977
Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer Research
2007
POEMS syndrome: definitions and long-term outcome
2003
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease [see comments]
1995 Standout
Depressive Illness and Placebo Response
1985
Patient evaluations of low back pain care from family physicians and chiropractors.
1989 Standout
Works of A Roth being referenced
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma
2007
5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere®)–cisplatin in advanced gastric carcinoma: a phase I–II trial
2004
POEMS syndrome presenting as systemic sclerosis
1988
Hemoglobin levels predict local regional control after postoperative radiotherapy for advanced head and neck cancer
1997
Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3)
2005
Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial)
2009
5FU as protracted continuous IV infusion (5FUpiv) can be added to full dose taxotere-cisplatin (TC) in advanced gastric carcinoma (AGC)
1999
Cytostatic treatment of metastatic cervical carcinoma.
1989
Treatment of metastatic brain tumors with the combination of 1-methyl-1-nitrosourea (MNU) and cyclophosphamide
1980
562 High doses of epirubicin and 5-fluorouracil with or without cisplatin in advanced gastric cancer
1995
Randomised clinical study (phase III) FE vs. FEP in advanced gastric cancer
1997
Who responds to sugar pills?
1976